Ocular varicella-zoster V1 virus activation after SARS-CoV-2 vaccination: 2 cases
Purpose
We are reporting a cases series of 2 patients who presented a VZV activation in the V1 dermatome with ocular involvement
Methods
2 patients were referred to our center as they presented an ophthalmic VZV episode within 2 weeks after vaccination for SARS-CoV-2 included a 53-year-old woman with history of ocular sarcoidosis and a 67-year-old woman with no history of autoimmune pathology. All patients presented the VZV infection after the 1st dose of a mRNA type of vaccine. Best corrected visual acuity (BCVA), slit lamp examination photos and measures of flare using laser flare photometry mesures are reported.
Results
Treatment with Valacyclovir 1000mg x 3/ day for 14 days was efficient in all cases. BCVA was 1.0 in all cases after the treatment
Conclusion
Vaccines have been reported in the past to trigger different types of side effects such as viral or flu-like symptoms. It is normal to note many different side effects for Sars-cov-2 vaccines as the population vaccinated is exceeding any other number in history. VZV is one of the more severe side effects that can, however be treated. It is quite obvious that, as far as mRNA vaccines are concerned, and probably also other anti-SARS-CoV-2 vaccines, the benefit of vaccination largely outweighs the possible but very low risk of ocular side effects that can mostly be treated
Conflict of interest
No
Authors 1
Last name
PAPASAVVAS
Initials of first name(s)
i
Department
Centre for Ophthalmic Specialised Care, Retinal and Inflammatory Eye Diseases
City
Lausanne
Country
Switzerland
Authors 2
Last name
Herbort Jr
Initials of first name(s)
C. P
Department
Centre for Ophthalmic Specialised Care, Retinal and Inflammatory Eye Diseases
City
Lausanne
Country
Switzerland
This website uses cookies to ensure you get the best experience on our website.
Learn more